U.S. Software Stock News

Analysts recently highlighted Vericel as a Growth at a Reasonable Price candidate, citing strong momentum in its earnings and revenue forecasts alongside a debt-free balance sheet and solid profitability metrics. This combination of projected earnings expansion, revenue growth and financial strength positions Vericel as a case study in how growth-focused investors may view profitable, balance-sheet-light businesses. With robust earnings growth projections at the center of the story, we’ll...

In the past few days, The Cooper Companies amended its 2021 term loan agreement, extending US$950 million of term loans to February 3, 2031, while lifting the cap on incremental borrowing and adding optional rating-based pricing. At the same time, Diamond Hill Capital’s Large Cap Fund disclosed a new position in the company, underscoring institutional interest in its contact lens and women’s health and fertility businesses despite current headwinds. Next, we’ll examine how the extended debt...

AXT (AXTI) is back on many watchlists after investor interest climbed alongside AI driven bandwidth demand, as the company’s Indium Phosphide substrate wafers sit at the heart of data center and optical communications build outs. See our latest analysis for AXT. AXT’s share price has been highly volatile, with a 14.8% 7 day share price return and a 116.9% 90 day share price return. The 1 year total shareholder return is extremely large, pointing to strong momentum despite the recent 5.7% 1...

If you are wondering whether Kyivstar Group's current share price reflects its true worth, you are not alone. This article focuses squarely on that question. The stock recently closed at US$11.83, with a 7 day return of 6.0% decline, a 30 day return of 10.9% decline, and a 1 year return of 14.4%, which points to shifting expectations and risk perceptions over different time frames. Recent news coverage around Kyivstar Group has focused on its position as a US listed telecom player with...

Samsara (NYSE:IOT) is expanding its Canadian footprint with local data hosting, domestic logistics partnerships, and new AI safety features. The rollout focuses on data residency, regional hardware fulfillment, and support for customers operating in remote parts of Canada. The company is tailoring its connected operations platform to Canadian fleets and industrial operators that face strict compliance and connectivity requirements. Samsara runs a connected operations platform that links...

If you are wondering whether Trane Technologies at around US$435 a share still offers reasonable value, you are not alone. This article is aimed at helping you frame that question clearly. The stock has posted returns of 11.0% over the last 7 days, 9.4% over the past month and year to date, and 23.6% over the past year, with a very large 3 year gain and a 219.1% return over 5 years that may be influencing how the market is thinking about future expectations and risk. Recent coverage has...

From what we can see, insiders were net buyers in Lindblad Expeditions Holdings, Inc.'s ( NASDAQ:LIND ) during the past...

If you are wondering whether Workiva at around US$72 per share offers fair value or a possible opportunity, you are not alone. That is exactly what this analysis will unpack. The stock has recently pulled back, with a 7 day return of an 11.1% decline, a 30 day return of a 13.2% decline, and a 1 year return of a 28.4% decline, which has also contributed to a 23.0% decline over 3 years and a 32.3% decline over 5 years. These moves have put Workiva on the radar for investors who track companies...

Sangamo Therapeutics recently reported detailed Phase 1/2 STAAR study results for its Fabry disease gene therapy, isaralgagene civaparvovec, and confirmed a rolling Biologics License Application submission to the FDA under the Accelerated Approval pathway, supported by kidney function as an intermediate clinical endpoint. The company paired these clinically promising data and regulatory progress with a roughly US$24.82 million follow-on equity raise and a finance leadership change,...

Ardelyx (ARDX) has drawn fresh attention after securing a new US patent that extends protection for its tenapanor formulations, IBSRELA and XPHOZAH, to 2042, while also advancing IBSRELA into a Phase 3 trial in chronic idiopathic constipation. See our latest analysis for Ardelyx. Ardelyx’s recent patent win and progress with the ACCEL Phase 3 trial come after a strong run, with a 30-day share price return of 25.85% and a 1-year total shareholder return of 40.22%, alongside a small pullback...

Labcorp Holdings (NYSE:LH) has amended its receivables purchase agreement, extending the facility’s termination date. The amendment adds an accordion feature that can increase borrowing capacity under certain conditions. The revised structure is intended to provide greater liquidity flexibility for the company’s operations and planning. Labcorp is a large diagnostics and laboratory services provider, so reliable access to funding is important for supporting day to day testing volumes and...

Why Central Bancompany is on investors’ radar today Central Bancompany (CBC) is drawing attention after a recent move in its share price, with the stock closing at $24.50 and showing varied returns over the past day, week, month, and past 3 months. See our latest analysis for Central Bancompany. While the 1 day share price return shows a 1.61% pullback to $24.50, the 90 day share price return of 15.29% sits alongside a 1 year total shareholder return of 89.00%. Together, these figures point...

If you are wondering whether WeRide's current share price offers value or just fresh risk, you are not alone. This article is going to focus squarely on what the numbers are saying about its valuation. WeRide's shares last closed at US$7.58, with returns of 14.3% decline over the past week, 19.3% decline over the past month, and 48.0% decline over the last year. This raises fair questions about how the market is currently pricing the stock. Recent news around autonomous driving regulation,...

If you are wondering whether Five9's current share price reflects its true worth, you are not alone. This article will walk through the key numbers that matter for valuation. Five9's share price closed at US$16.71, with returns of a 9% decline over 7 days, an 11.2% decline over 30 days, an 11.2% decline year to date, a 60.8% decline over 1 year, an 80.2% decline over 3 years and a 90.6% decline over 5 years, which naturally raises questions about both risk and potential. Recent coverage has...

If you are wondering whether UniFirst at around US$203 is a fair deal or a stretch, you are not alone. This article is built to help you frame that question clearly. The stock has seen mixed returns, with a 4.9% gain over the past month and year to date, against a 3.2% decline over the last 7 days and an 8% decline over the past year. These moves may have shifted how some investors view its potential and risks. Recent coverage around UniFirst has largely focused on the company as a long...

Alphabet recently moved to dramatically expand its footprint in India, securing rights to up to 2.4 million square feet of office space in Bengaluru that could house as many as 20,000 additional employees, while its Waymo unit raised US$16 billion at a US$126 billion valuation and investors looked ahead to Q4 2025 earnings. Together, the India build-out, Waymo funding, and Gemini- and cloud-focused expectations highlight how Alphabet is tying long-term AI and autonomous-mobility ambitions to...

Dividend recovery and portfolio reshaping at W. P. Carey W. P. Carey (WPC) is back in focus after cutting its dividend in late 2023, then raising it for eight straight quarters while cycling US$1.5b of dispositions into US$2.1b of new properties. See our latest analysis for W. P. Carey. At a share price of US$69.25, W. P. Carey has seen a 6.77% year to date share price return and a 32.80% one year total shareholder return. This suggests that recent dividend progress and portfolio reshaping...

If you are wondering whether Guardant Health at US$113.05 is starting to look expensive or still offers value, you are not alone in asking that question right now. The stock has seen a 1.3% decline over the last 7 days, an 11.1% return over the last 30 days and year to date, a 139.7% return over the last year, a 295.8% return over 3 years, and a 30.8% decline over 5 years. This may suggest the market’s view of its risk and potential has shifted over different time frames. Recent coverage has...

Tencent Music Entertainment Group (NYSE:TME) has formed a new joint venture called ONECEAD with CJ ENM and JYP China. The partnership focuses on developing, launching and managing next generation artists for global audiences. ONECEAD is intended to combine music production, artist management and content distribution capabilities across China, Korea and international markets. For investors watching NYSE:TME, this move comes with the stock at $16.4 and a 1 year return of 38.2%. Over 3 years,...

If you are wondering whether ADMA Biologics at US$17.52 still offers value or has already run too far, this breakdown will help you put the current share price in context. The stock has had mixed returns, with a 7.3% gain over the last week, a 2.8% decline over the last month, a 2.0% decline year to date, a 3.9% return over the past year, and a very large return over three and five years. Recent coverage of ADMA Biologics has focused on its share price performance over different time frames,...

Coty recently announced a collaboration with OpenAI to roll out ChatGPT Enterprise across selected parts of its global organization, aiming to support employees’ daily work, creativity and cross‑functional collaboration with enterprise-grade AI tools. This move positions Coty as an early adopter of advanced AI within the beauty industry, potentially reshaping how it manages innovation, efficiency and internal decision-making. We will now examine how Coty’s adoption of ChatGPT Enterprise...

If you are wondering whether Horace Mann Educators at around US$44.92 still offers value, an important question is how its current price compares with what the business may be worth. The stock has returned 4.7% over the last 7 days, while the 1 year return sits at 21.7% and the 3 year return at 38.6%. A 0.6% decline year to date may suggest that expectations and risk perceptions are changing. Recent coverage has focused on Horace Mann Educators as an insurer serving the education community,...

Key Insights The considerable ownership by private companies in GDEV indicates that they collectively have a greater...

Key Insights The considerable ownership by individual investors in NovaBridge Biosciences indicates that they...